Every year, more than 20,000 Americans receive a bone marrow transplant — a Nobel prize-winning procedure that saves many lives but also carries great risk. For leukemia patients, it's a choice of last resort, as nearly 20% die from the transplant. Ivan Dimov, co-founder & CEO of Orca Bio, and his team have created a novel cell therapy alternative that has already saved over 400 lives in clinical trials with virtually zero rejection!This week, we dive into Ivan's journey, the science behind Orca's cancer breakthrough, and the potential of cell therapies to cure a host of other diseases.  By discovering new, high-precision methods to manipulate cells, Orca is able to provide leukemia patients with a designer immune system that attacks the cancer while nearly eliminating rejection. By safely rebooting the immune system, Ivan and his team believe Orca also has the potential to cure autoimmune diseases like Crohn’s disease and multiple sclerosis, and impact the lives of millions of Americans.Orca is currently seeking the first-ever FDA approval in this space, and since it's a unique one-time curative therapy, they are also commercializing the drug in-house — a rare move in biopharma. Ivan walks us through the path to bringing Orca's products to market, from collaborating with regulators to negotiating with insurance companies and scaling up its manufacturing. Though many challenges remain, you'll see why we're incredibly bullish on Ivan's leadership and Orca's potential to transform the future of medicine.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit blog.joelonsdale.com